Belgian Life Science Investor Exceeds Expectations With New €125m Fund
Executive Summary
Fund+ has beaten its €100m target to raise €125m for life science investment in Europe – making it the largest private biotech fund in Belgium.
You may also be interested in...
Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH
Emerging Company Profile: Belgium’s Promethera presented preclinical data for HepaStem, its liver-derived stem cell candidate for NASH, fibrosis and acute-on-chronic liver disease, at the AASLD meeting. With what appears to be a solid safety profile, the company hopes to move into clinical studies in the near term.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.